DNA Chip Research Inc.

2397

JP3548590003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-21 am EDT			5-day change	1st Jan Change
927 ^JPY	-3.03%		-12.22%	+33.96%

Mar. 28	DNA Chip Research Inc. announced that it has received ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI
Feb. 08	DNA Chip Research Inc. announced that it expects to receive ¥269.99972 million in funding from Mitsui Chemicals, Inc.	CI

DNA Chip Research Inc. announced that it has received ¥3.92 million in funding from Daiwa Securities Co. Ltd.

March 05, 2020

On March 6, 2020, DNA Chip Research Inc. (TSE:2397) closed the transaction.

Latest news about DNA Chip Research Inc.

DNA Chip Research Inc. announced that it has received ¥269.99972 million in funding from Mitsui Chemicals, Inc.	Mar. 27	CI
DNA Chip Research Inc. announced that it expects to receive ¥269.99972 million in funding from Mitsui Chemicals, Inc.	Feb. 07	CI
DNA Chip Research Inc. announced that it has received ¥279.99974 million in funding from Mitsui Chemicals, Inc.	23-02-20	CI
DNA Chip Research Inc. announced that it expects to receive Ã‘279.99974 million in funding from Mitsui Chemicals, Inc.	23-01-22	CI
DNA Chip Research Inc. announced that it has received ¥3.92 million in funding from Daiwa Securities Co. Ltd.	20-03-05	CI
DNA Chip Research Inc. announced that it expects to receive ¥3.92 million in funding from Daiwa Securities Co. Ltd.	20-02-18	CI
DNA Chip Research Inc. announced that it has received ¥630.62 million in funding from Enplas Corporation.	14-12-07	CI
DNA Chip Research Inc. announced that it expects to receive ¥567.31 million in funding from Enplas Corporation.	14-11-18	CI

DNA Chip Research Inc. is primarily engaged in DNA chip-related analysis and next-generation sequence related technology research business, and diagnostic business which is engaged in the sales of medical-related equipment centered on EGFR-NGS Check. The Contract Research segment is engaged in the microarray, next-generation sequencing experiment analysis to universities and research institutes, pharmaceutical and food companies. The Diagnostic segemnt utilizes genetic analysis technology to disseminate tests corresponding to social needs on personalized medicine and undiseased society. The main menu of the diagnostic business is EGFR-NGS Check. The Research and Development segment includes research on cancer diagnosis technology using next generation sequencer, as well as the development of RNA check.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
DNA CHIP RESEARCH INC.	+33.96%	41.45M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+47.64%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research